The burden of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is disproportionately high among men, yet empirical evidence regarding the difference in prevalence of oral HPV infection between men and women is limited. Concordance of oral and genital HPV infection among men is unknown.
(1.8% [CI, 1.3% to 2.2%]) than women (0.3% [CI, 0.1% to 0.5%]) (1.7 million men vs. 0.27 million women). Among men and women who reported having same-sex partners, the prevalence of high-risk HPV infection was 12.7% (CI, 7.0% to 18.4%) and 3.6% (CI, 1.4% to 5.9%), respectively. Among men who reported having 2 or more same-sex oral sex partners, the prevalence of high-risk HPV infection was 22.2% (CI, 9.6% to 34.8%). Oral HPV prevalence among men with concurrent genital HPV infection was 4-fold greater (19.3%) than among those without it (4.4%). Men had 5.4% (CI, 5.1% to 5.8%) greater predicted probability of high-risk oral HPV infection than women. The predicted probability of high-risk oral HPV infection was greatest among black participants, those who smoked more than 20 cigarettes daily, current marijuana users, and those who reported 16 or more lifetime vaginal or oral sex partners.
Limitation:
Sexual behaviors were self-reported.
Conclusion:
Oral HPV infection is common among U.S. men. This study's findings provide several policy implications to guide future OPSCC prevention efforts to combat this disease. H uman papillomavirus (HPV) infection causes cancer at several anatomical sites, including the oropharynx, anus, and penis in men and the oropharynx, anus, cervix, vagina, and vulva in women (1) . Between 2008 and 2012, an average of 38 793 cases of HPV-related cancer were diagnosed annually in the United States, 23 000 (59%) in women and 15 793 (41%) in men (2) . Among these cases, the most common cancer was oropharyngeal squamous cell carcinoma (OPSCC), of which there were 3100 cases in women and 12 638 in men (2) .
Primary Funding
The incidence of HPV-related OPSCC among women generally plateaued (with a statistically insignificant increase of 0.57% per year) from 2002 to 2012 (3). In contrast, the incidence among men (7.8 per 100 000) has increased dramatically (2.89% per year) and has already surpassed the incidence of cervical cancer in women (7.4 per 100 000) (3). The increase in annual incidence was particularly high in men aged 50 to 59 years: 7.75% from 2002 to 2004 and 2.44% from 2004 to 2010 (3). These incidence trends are projected to continue and not reverse until after 2060, making OPSCC a significant public health concern (4, 5) .
Recent evidence shows that prophylactic HPV vaccination seems to protect against infection with vaccine-covered oral HPV subtypes (6) and thus holds promise for reversing the rising OPSCC incidence among men in the long term; however, the low uptake rate of the vaccine among boys remains a concern (7) (8) (9) . Furthermore, the great majority of persons at risk for OPSCC are older than 26 years (4) and do not qualify for HPV vaccination or may already have been exposed to HPV. For this reason, epidemiologic studies on oral HPV infection are needed to guide the design and development of alternative OPSCC prevention strategies targeted toward persons at high risk. Examining the relationship between HPV infections occurring at different anatomical sites also is crucial to understanding HPV transmission dynamics. Therefore, our objective was twofold: to estimate the population-based preva- 
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lence and risk factors of oral HPV infection by sex and sexual orientation and to characterize the concordance of oral and genital HPV infection from the NHANES (National Health and Nutrition Examination Survey).
METHODS
Survey Design and Population
The NHANES is conducted by the National Center for Health Statistics of the Centers for Disease Control and Prevention to monitor the health and nutritional status of the U.S. population. Participants in NHANES 2011 to 2014 were noninstitutionalized U.S. civilians identified through a stratified, multistage probability sampling technique. Participants aged 18 to 69 years had a physical examination at a mobile examination center (MEC), followed by a household interview. Hispanic persons, African Americans, persons with low income, and those aged 60 years and older were oversampled to allow sufficient sizes for subgroup analysis.
The medical examinations done at the MEC included medical, dental, and physiologic measurements and laboratory tests administered by highly trained medical personnel. The household interview component consisted of standardized questionnaires on demographics, socioeconomic status, diet, and sexual behavior administered through a personal or phone interview.
Demographic and Behavioral Data
The NHANES collected demographic data through a standard questionnaire administered in-home by trained interviewers using a computer-assisted personal interviewing system. Data on cigarette, alcohol, and marijuana use were collected during the MEC selfinterview. Demographic data included age at the time of the interview, sex, race, marital status, and income. Income-to-poverty ratio was calculated by dividing income by the poverty guidelines of the U.S. Department of Health and Human Services specific to the survey year. Use of birth control pills and hormone therapy was self-reported by female participants.
Self-reported sexual behavior data-for example, ever having had sex (vaginal, anal, or oral), sexual orientation, ever having had a same-sex sexual partner, number of oral sex partners during the past 12 months, age at first oral sex, and barrier use during oral sex in the past 12 months-were collected at the MEC through a standardized questionnaire. History of herpes or warts and HPV infection also was self-reported. HIV positivity was based on HIV-antibody test results.
Specimen Collection and Laboratory Methods
A dental hygienist collected oral rinse specimens in sterile collection cups. Each participant was asked to swish a 10-mL sample of a mouthwash or sterile solution in his or her mouth and then expectorate the sample into the sterile cup. The MEC laboratory technologist transferred each sample from the collection cup to a 14-mL Falcon snap cap tube (Fisher Scientific) and shipped it to the laboratory for testing. Details of sample collection, quality control, and laboratory methods may be found in the MEC Laboratory Procedures Manual on the NHANES Web site (10) and in a previously published study (11) .
The specimens were analyzed as previously described (11) . ␤-Globin-positive samples were considered evaluable. Each purified DNA sample was analyzed by polymerase chain reaction assay. The Roche Linear Array HPV Genotyping test was used for detection of 37 HPV types, including high-risk types (HPV 16, 18, 26, 31, 33, 35,  (12) .
Concordance of Oral and Genital HPV
Concurrent overall genital and oral HPV infection was defined as an infection in both the genital and oral regions, regardless of HPV type. Concurrent high-risk genital and oral HPV infection was defined as an infection with any high-risk type in both the genital and oral regions. Similarly, concurrent type-specific infection was defined as an infection with a specific HPV type (such as HPV 16) in the genital and oral regions. Details of specimen collection and laboratory methods for genital HPV detection among men and women may be found on the NHANES Web site and in previously published studies (13, 14) .
Statistical Analysis
We estimated the prevalence of overall, high-risk, low-risk, and type-specific oral HPV, as well as prevalence by demographics and sexual behaviors, for men and women aged 18 to 69 years by using NHANES 2011 to 2014. Concordance of genital and oral HPV infection was estimated for adults aged 18 to 59 years by using NHANES 2013 to 2014. A survey designadjusted Wald F test was used for bivariate analyses, and the Cochran-Armitage test was performed to detect trends in prevalence. Prevalence estimates with a relative SE greater than 30% or based on 10 or fewer positive cases are noted; these are considered unstable and should be interpreted with caution. The differences in predicted probability between levels of risk factors for overall and high-risk oral HPV infection were estimated by using logistic regression models. Variables in logistic regression models were selected on the basis of bivariate associations. Statistical significance was tested at P < 0.05. All analyses were performed by using SAS 9.4 software (SAS Institute). For population estimates, we used SAS PROC SURVEY procedures, which included weight, cluster, and strata statements, to incorporate sampling weights.
Role of the Funding Source
The funders had no role in the study design or conduct or in the reporting of results.
Prevalence of Oral HPV Infection Among Men and Women
The prevalence of overall oral HPV infection among men and women was 11.5% (95% CI, 9.8% to 13.1%) and 3.2% (CI, 2.7% to 3.8%), respectively, equating to 11 million men and 3.2 million women nationwide. Similarly, the prevalence of high-risk HPV infections was higher among men (7.3% [CI, 6.0% to 8.6%]; 7 million) than women (1.4% [CI, 1.0% to 1.8%]; 1.4 million) (P < 0.001). The type-specific prevalence of high-risk and low-risk HPV infection is shown in Figure 1 , A and B, respectively. Notably, the prevalence of HPV 16, the most common type, was sixfold higher among men (1.8% [CI, 1.3% to 2.2%]; 1.7 million) than women (0.3% [CI, 0.1% to 0.5%]; 0.27 million) (P < 0.001). The prevalence of all high-risk and low-risk HPV types was consistently higher in men than women. The age-specific prevalence of vaccine-covered 9-valent, 4-valent, The prevalence of overall and high-risk oral HPV infection was significantly associated with cigarette and marijuana use among men and women ( Table 1 ). The prevalence of overall oral HPV infection was highest (overall, 23.6%; high-risk, 15.0%) among men who smoked more than 20 cigarettes a day and was lowest (overall, 8.3%; high-risk, 5.4%) among never-smokers and former smokers. The prevalence was highest among men who were former marijuana users (overall, 13.4%; high-risk, 9.4%). Among women, the highest prevalence of oral HPV infection was in current marijuana users (overall, 7.9%; high-risk, 3.0%).
We found no significant difference in the prevalence of overall and high-risk HPV infection between participants who received the HPV vaccine and those who did not ( Table 1) . However, among HPV vaccineeligible persons who were reportedly vaccinated, we found that the prevalence of 4-valent types was significantly lower than in unvaccinated persons (0.18% vs. 1.47%; P < 0.001) (Supplement Figure 3 , available at Annals.org). Similarly, the difference remained statistically significant in men (0.41% vs. 1.97%; P = 0.019).
The prevalence of oral HPV infection was significantly associated with sexual and behavioral characteristics among men and women (Appendix Table, available at Annals.org). The prevalence of high-risk HPV infection was 8, 10, and 4 times higher in men who reported having more than 16 lifetime sex partners (any, oral, or vaginal, respectively) than in those with 1 or no lifetime sex partners. Similarly, the prevalence in women who reported such behavior was 7, 3, and 6 times higher than in those with 1 or no lifetime sex partners (any, oral, and vaginal, respectively). When restricted to number of sex partners in the past 12 months, the prevalence of oral HPV (both overall and high-risk) was highest among men with 2 or more any and oral sex partners. Results were similar for women but not statistically significant.
Among men and women who reported having same-sex partners, the prevalence of high-risk HPV infection was 12.7% (CI, 7.0% to 18.4%) and 3.6% (CI, 1.4% to 5.9%), respectively; whereas among men and women who did not report this behavior, it was 6.8% and 1.2%, respectively. In particular, the prevalence of high-risk HPV infection was highest (22.2% [CI, 9.6% to 34.8%]) among men who reported having 2 or more lifetime same-sex oral sex partners. No statistically significant difference in prevalence was found with regard to lifetime number of anal sex partners among men who reported having same-sex partners. Figure 2 illustrates the prevalence of oral HPV infection with and without concurrent genital HPV infection among men and women (overall and by age and race). The prevalence of overall (Figure 2 , A) and highrisk ( Figure 2 , B) oral HPV infections among men with concurrent genital overall or high-risk HPV infection was 19.3% and 13.7%, respectively, whereas the prevalence among men without such infections was 4.4% and 3.9%. Similarly, the prevalence of overall (5.1%) and high-risk (3.2%) oral HPV infection was almost threefold higher in women with concurrent genital HPV infection than in those without such infections (overall, 2.1%; high-risk, 1.1%). We also present vaccinecovered 9-valent, 4-valent, 2-valent, and HPV-16 oral infection prevalence among men and women with or without genital HPV infection in Supplement Figure 4 (available at Annals.org).
Prevalence of Oral HPV Infection Concurrent With Genital HPV Infection
When stratified by age ( Figure 2 , C and D), the prevalence of oral HPV infection increased with age among men with or without concurrent genital HPV infection (P < 0.001 for trend). When stratified by race ( Figure 2 , E and F), we found no significant difference in prevalence of oral HPV infection, regardless of the presence or absence of genital HPV infection. Among both men and women, when stratified by lifetime number of sexual partners, we found that regardless of the presence or absence of concurrent genital HPV infection, the prevalence of oral HPV infection increased with number of sexual partners (any, oral, or vaginal) (Appendix Figure, available at Annals.org). We further report prevalence of oral HPV among men and women with genital HPV infection by age and lifetime number of sexual partners in Supplement Figures 5 and 6 (available at Annals.org).
Predicted Probability of Oral HPV Infection
The differences in predicted probability between levels of risk factors for overall and high-risk oral HPV infection are presented in Table 2 . The predicted probability for overall oral HPV infection was 7.6% (CI, 7.1% to 8.2%) and that for high-risk oral HPV infection was 5.4% (CI, 5.1% to 5.8%) greater for men than women. Compared with white participants, black participants had a greater risk for overall (predicted probability, 3.3% [CI, 2.7% to 3.9%] greater) and high-risk (predicted probability, 1.2% [CI, 0.8% to 1.6%] greater) oral HPV infection. Hispanic participants had a greater risk for overall oral HPV infection (predicted probability, 0.7% [CI, 0.1% to 1.3%] greater) than white participants; however, their risk for high-risk oral HPV infection was lower (predicted probability, Ϫ0.6% [CI, Ϫ1.0% to Sex Differences in Prevalence and Concordance of Oral vs. Genital HPV ORIGINAL RESEARCH . Increase in daily cigarette consumption was associated with a greater risk for overall and high-risk oral HPV infection. The risk for participants who smoked more than 20 cigarettes daily was highest-9.6% and 8.0% greater predicted probability for overall and high-risk oral HPV infection, respectively, compared with never or former smokers. Participants who reported current marijuana use had a 6.4% greater risk for overall and 4.5% greater risk for high-risk oral HPV infection than those who never used marijuana. Participants who reported having 16 or more lifetime vaginal sex partners had the greatest risk for overall (predicted probability, 11.1% greater) and high-risk (predicted probability, 7.9% greater) oral HPV infection compared with those who had 1 or no lifetime vaginal sex partners. Similarly, the risk for overall (predicted probability, 18.3% greater) and high-risk (predicted probability, 13.0% greater) oral HPV infection was highest for participants with 16 or more lifetime oral sex partners. We also report differences in predicted probability between levels of risk factors for concordant oral-genital HPV infection in Supplement Table 3 (available at Annals.org).
DISCUSSION
The prevalence of high-risk oral HPV infection in the United States is substantially higher in men than women. We found that 7.3% of men and 1.4% of women in the general population have high-risk oral HPV infection, which equates to 7 million men and 1.4 million women, respectively. In particular, the prevalence of HPV 16, an oncogenic HPV type known to contribute to increased risk for OPSCC, is 6 times greater in men than women, equating to 1.7 million men and 0.27 million women with HPV 16 infection.
We found that when characterized by age, the prevalence of high-risk oral HPV infection in both men and women peaked at age 50 to 54 years. A large multinational cohort study-HIM (HPV Infection in Men)-found that the acquisition of high-risk oral HPV infection was constant across age groups (15) . Therefore, the prevalence peak we observed in older participants in our study may have been the result of a longer duration of infection at older ages (15, 16) . We found that oncogenic HPV 16 was most prevalent in men aged 50 to 69 years. Data from the HIM study indicate that the high HPV 16 prevalence among older men might be attributed to longer persistence of infection (17) . The study reported that prevalent oral HPV 16 infection persisted longer than newly acquired infections and that the persistence of incident HPV 16 infection increased significantly with age (17) . Given that OPSCC incidence is greatest in this age group of men (4), determining whether persistent HPV 16 infection plays a role in the observed excess prevalence of oral HPV 16 infection is crucial, particularly because persistent infection might be driving OPSCC carcinogenesis in older men.
We found that the prevalence of oral HPV infection was high among men with concurrent genital HPV infection. This finding is particularly important given the recently reported high prevalence of genital HPV infection (45.2% [CI, 41.3% to 49.3%]) among U.S. men (13) . To our knowledge, only 1 study, from rural China, studied oral-genital HPV concordance and found that the prevalence of oral HPV infection was higher among men with concurrent genital HPV infection (11.4%) than those without it (5.7%) (18) . Steinau and colleagues (19) studied oral and anal (another anatomical site) concordance among men who have sex with men and found that participants were more likely to have any oral HPV if they also had any anal HPV (relative risk, 1.16 [CI, 1.05 to 1.28]).
The consistent association between sexual behaviors (such as lifetime number of sex partners) and the high prevalence of oral HPV infection among adults with genital HPV infection observed in our study implies that transmission via genital-oral sex may be occurring in this group (20 -22) . In addition, oral HPV infection likely is acquired via autoinoculation from genital HPV infection, or vice versa, through fingers in the same individual (23) . Further study of HPV transmission dynamics is crucial, because the bidirectional transmission between genital and oral HPV likely is promoting HPV-related cancer in the same individuals or contributing to the increased risk of second primary HPV-related cancer in men (24) . Finally, the observed discrepancy between oral-genital HPV concordance rates among men and women may be the result of differences in the size of HPV sampling area and circumcision status of their male partners (25) .
The difference in burden of oral oncogenic infection and OPSCC among men and women is partially explained by the strength of association between sexual behaviors and HPV infection among men (26) and, as observed in our study, a higher prevalence of HPV 16 infection in men. Another possibility is that seroconversion rates after genital HPV infection are lower in men than women, leading to greater protection against subsequent oral HPV infection in women (1, 27) . Our findings indicate that association between HPV infections at oral and genital sites also might be contributing to this heterogeneity between sexes. The incidence of OPSCC in women, like that of cervical cancer, is decreasing in the United States (5). Because of increased prevention efforts, such as screening, and given the positive association between high-risk genital and oral HPV, the decline in OPSCC incidence in women may be mirroring the decline in cervical cancer incidence (28) . Likewise, OPSCC incidence trends paralleled increased rates of genital warts and genital herpes among men (29) . Studies also attributed these incidence trends to a birth cohort effect predicting that the relative incidence of OPSCC among men will continue to increase for at least 30 more years (28, 30) .
We examined several risk factors for oral HPV infection. As reported in prior studies, we also observed a dose-response association between oral HPV prevalence and cigarette use (11, 31) . The exact pathophysiologic mechanism of this association is unknown; however, that smoking induces proinflammatory and immunosuppressive effects, increasing risk for HPV in-ORIGINAL RESEARCH Sex Differences in Prevalence and Concordance of Oral vs. Genital HPV 
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cidence and persistence at the oropharynx, has been suggested (32, 33) . The predicted probability of oral HPV infection was greatest among participants who had 16 or more lifetime oral sex partners. This finding is consistent with a previous study showing that persons who have had many oral sex partners have greater odds of oral HPV infection (34) . Similar to the findings of Hirth and colleagues (6), our results suggest that HPV vaccination prevents oral vaccine-covered HPV subtype infections in vaccineeligible persons. AIDS Clinical Trials Group protocol A5298, a randomized double-blind trial of quadrivalent HPV vaccination in HIV-infected adults older than 27 years, found that HPV vaccination reduced the risk for persistent oral infection with vaccine types (hazard ratio, 0.12 [CI, 0.02 to 0.98]), but the number of events was low: 1 event among vaccine recipients compared with 8 events among placebo recipients (35) . Further research is needed to determine whether HPV vaccination protects against oral HPV infection across all age groups of the general population of men and whether the incidence of HPV-related OPSCC is lower among recipients of the HPV vaccine. Future decision analyses also are needed to estimate the value of vaccinating middle-aged men to reduce the expanding epidemic of HPV-associated OPSCC.
The primary limitation of our study was insufficient sample sizes to determine certain associations, such as prevalence of 4-valent types by HPV vaccination doses. However, the use of 2 NHANES panels allowed a sample large enough to report what we believe are the most comprehensive data available to date on high-risk oral HPV prevalence and genital-oral HPV concordance among men and women. Concordance of oral-genital HPV infection was studied by using only 1 NHANES panel (2013 to 2014). Caveats exist regarding the stability of prevalence estimated by using 1 cycle of NHANES data; therefore, our findings should be interpreted cautiously. Certain inherent limitations are associated with NHANES data. Self-reported behaviors-for example, sexual behaviors-likely are underreported because of social stigma and recall bias. However, selfreport is the only way to obtain these data and is considered a standard practice. Finally, comparing our estimates with other non-NHANES studies should be done cautiously, because other studies may have 
